Dolutegravir—a promising antiretroviral in development-Reference-Cited by-同舟云学术

Dolutegravir—a promising antiretroviral in development

Published:2012-02 Issue:2 Volume:12 Page:90-91
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Boyd Mark

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference11 articles.

1. HIV disease progression in Australia in the time of combination antiretroviral therapies;Correll;Med J Aust,1998

2. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies;Lancet,2008

3. Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals;van Sighem;AIDS,2010

4. Adverse effects of antiretroviral therapy;Carr;Lancet,2000

5. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial;van Lunzen;Lancet Infect Dis,2011

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mind bomb 2 limits inflammatory dermatitis in Sharpin mutant mice independently of cell death;PNAS Nexus;2023-12-18

2. Conversion of raltegravir carrying a 1,3,4-oxadiazole ring to a hydrolysis product upon pH changes decreases its antiviral activity;PNAS Nexus;2023-12-18

3. Current status of dolutegravir delivery systems for the treatment of HIV-1 infection;Journal of Drug Delivery Science and Technology;2022-10

4. An Improved Preparation of (R)-3-Aminobutanol, a Key Intermediate for the Synthesis of Dolutegravir Sodium;Letters in Drug Design & Discovery;2017-10-31

5. Novel Second Generation HIV Integrase Inhibitor-DOLUTEGRAVIR: An Emerging Weapon Against HIV;Letters in Drug Design & Discovery;2017-01-26